

Vevorisertib trihydrochloride Biochemical

Vevorisertib trihydrochloride

CATALOG #
AAA227664


PRODUCT SYNONYMS

Vevorisertib trihydrochloride; Vevorisertib trihydrochloride biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1416775-08-0
Targets&IC50	Akt3:1.31 nM (IC50), Akt1 E17K:8.6 nM (Kd), Akt2:0.81 nM (IC50), Akt1:0.55 nM (IC50), Akt1:1.2 nM (Kd)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Vevorisertib trihydrochloride (25, 50 and 75 mg/kg; p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days) shows potent tumor growth inhibition of 68, 78 and 98%, respectively[1]. Vevorisertib trihydrochloride (5, 10, 20, 40, 80, and 120 mg/kg; p.o. daily for ten days) shows tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively[1]. Vevorisertib trihydrochloride reaches C max plasma concentrations of ≥ 2 uM[1]. Vevorisertib trihydrochloride is generally well-tolerated at dose levels up to 120 mg/kg[1]. Vevorisertib trihydrochloride (MK-4440)/IM combination shows superior efficacy in an IM-sensitive preclinical model of GIST compared with either single agent[2]. Animal Model: Endometrial PDX mouse xenograft models (AKT1-E17K mutation tumor fragments subcutaneously implanted in athymic nude mice; tumor volume of approximately 200 mm ³)[1]. Dosage: 25, 50 and 75 mg/kg. Administration: p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days. Result: Showed potent tumor growth inhibition of 68, 78 and 98%, respectively. Animal Model: AN3CA mouse xenograft models (female NCr nu/nu mice with 250 mm ³ tumors size)[1]. Dosage: 5, 10, 20, 40, 80, and 120 mg/kg. Administration: p.o.; daily for ten days. Result: Showed tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Ezurpimtrostat, CAS 1914148-72-3



Structure
Ezurpimtrostat, CAS 1914148-72-3

ADDITIONAL INFORMATION

Related Product Information for Vevorisertib trihydrochloride biochemical	Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan- AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC 50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer.
References	1. HALFON PHILIPPE, et al. SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES. WO2020048694 A1.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/vevorisertib-trihydrochloride/227664>